Cargando…

Effects of tolvaptan on renal function in chronic kidney disease patients with volume overload

BACKGROUND: Fluid overload in chronic kidney disease (CKD) is generally controlled by diuretics, with potentially harmful effects on renal function. The efficacy of tolvaptan, a vasopressin V2-receptor antagonist and aquaretic, has not been evaluated for fluid control in CKD with reduced renal funct...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suzuki, Shunji, Hanafusa, Norio, Kubota, Kenji, Tsuchiya, Ken, Nitta, Kosaku
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6103308/ https://www.ncbi.nlm.nih.gov/pubmed/30147354 http://dx.doi.org/10.2147/IJNRD.S167694

Ejemplares similares

Denosumab Recovers Aortic Arch Calcification During Long-Term Hemodialysis
por: Suzuki, Shunji, et al.
Publicado: (2020)

Management of Osteoporosis in Chronic Kidney Disease
por: Nitta, Kosaku, et al.
Publicado: (2017)

Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease
por: Tsuruta, Yuki, et al.
Publicado: (2014)

Urinary Aquaporin 2 as a Potential Indicator Predicting Tolvaptan Response in Patients With ADPKD
por: Makabe, Shiho, et al.
Publicado: (2021)

High Serum Phosphate Level as a Risk Factor to Determine Renal Prognosis in Autosomal Dominant Polycystic Kidney Disease: A Retrospective Study
por: Sato, Masayo, et al.
Publicado: (2020)

A new paradigm for the treatment of volume overload in heart failure-combined effect of tolvaptan with furosemide
por: Okamoto, Hiroshi
Publicado: (2013)

Sphingosine‐1‐phosphate acts as a key molecule in the direct mediation of renal fibrosis
por: Shiohira, Shunji, et al.
Publicado: (2013)

Impact of kidney function and kidney volume on intracranial aneurysms in patients with autosomal dominant polycystic kidney disease
por: Kataoka, Hiroshi, et al.
Publicado: (2022)

Visceral to subcutaneous fat ratio as an indicator of a ≥30% eGFR decline in chronic kidney disease
por: Kataoka, Hiroshi, et al.
Publicado: (2020)

The roles of sodium and volume overload on hypertension in chronic kidney disease
por: Shin, Jinho, et al.
Publicado: (2021)

Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure
por: Katsumata, Mari, et al.
Publicado: (2017)

Fibroblast growth factor 23 is upregulated in the kidney in a chronic kidney disease rat model
por: Sugiura, Hidekazu, et al.
Publicado: (2018)

Germline Mutations for Kidney Volume in ADPKD
por: Kataoka, Hiroshi, et al.
Publicado: (2021)

The Efficacy and Renal Protective Effect of Tolvaptan in Chronic Kidney Disease Patients after Open-Heart Surgery
por: Futamura, Yasuhiro, et al.
Publicado: (2021)

Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease
por: Horie, Shigeo, et al.
Publicado: (2021)

Autosomal Dominant Polycystic Kidney Disease with Emphysematous Polycystic Renal Infection That Required Surgical Treatment
por: Watanabe, Kentaro, et al.
Publicado: (2018)

Tolvaptan in ADPKD Patients With Very Low Kidney Function
por: Torres, Vicente E., et al.
Publicado: (2021)

Impaired Renal Function May Not Negate the Efficacy of Tolvaptan in the Treatment of Cirrhotic Patients with Refractory Ascites
por: Arase, Yoshitaka, et al.
Publicado: (2018)

Long-term effects of contrast media exposure on renal failure progression: a retrospective cohort study
por: Takura, Tomoyuki, et al.
Publicado: (2023)

Acute heart failure volume control multicenter randomized (AVCMA) trial: Comparison of tolvaptan and carperitide
por: Suzuki, Satoshi, et al.
Publicado: (2013)

Possible Link between Metabolic Syndrome and Chronic Kidney Disease in the Development of Cardiovascular Disease
por: Nitta, Kosaku
Publicado: (2010)

Efficacy of tolvaptan on advanced chronic kidney disease with heart failure: a randomized controlled trial
por: Komiya, Shiro, et al.
Publicado: (2022)

Relationship between Fibroblast Growth Factor-23 and Mineral Metabolism in Chronic Kidney Disease
por: Nitta, Kosaku
Publicado: (2010)

Maximum Carotid Intima-Media Thickness in Association with Renal Outcomes
por: Manabe, Shun, et al.
Publicado: (2021)

Tolvaptan, Kidney Function Decline, and Potential Confounding by Muscle Wasting
por: Groothof, Dion, et al.
Publicado: (2023)

Volume Overload and Adverse Outcomes in Chronic Kidney Disease: Clinical Observational and Animal Studies
por: Hung, Szu-Chun, et al.
Publicado: (2015)

Tolvaptan
por: Rangarajan, Bharath, et al.
Publicado: (2014)

The effects of tolvaptan on patients with severe chronic kidney disease complicated by congestive heart failure
por: Otsuka, Tomoyuki, et al.
Publicado: (2013)

Impact of chronic kidney disease on the diuretic response of tolvaptan in acute decompensated heart failure
por: Ikeda, Shuntaro, et al.
Publicado: (2017)

Visceral fat and attribute-based medicine in chronic kidney disease
por: Kataoka, Hiroshi, et al.
Publicado: (2023)

Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function
por: Shoaf, Susan E, et al.
Publicado: (2014)

Different Effects on Fluid Distribution between Tolvaptan and Furosemide in a Liver Cirrhosis Patient with Chronic Kidney Disease
por: Nagayama, Izumi, et al.
Publicado: (2019)

Are there any further modalities for prediction of subclinical volume overload in advanced stages of chronic kidney disease?
por: Baki, Aber Halim, et al.
Publicado: (2021)

Sex Differences in Time-Series Changes in Pseudo-R(2) Values Regarding Hyperuricemia in Relation to the Kidney Prognosis
por: Kataoka, Hiroshi, et al.
Publicado: (2020)

Dual Impact of Tolvaptan on Intracellular and Extracellular Water in Chronic Kidney Disease Patients with Fluid Retention
por: Masuda, Takahiro, et al.
Publicado: (2016)

Tolvaptan Improves Contrast-Induced Acute Kidney Injury
por: Xu, Chunyang, et al.
Publicado: (2022)

Renal biopsy findings and clinical indicators of patients with hematuria without overt proteinuria
por: Hoshino, Yoshie, et al.
Publicado: (2015)

Elobixibat alleviates chronic constipation in hemodialysis patients: a questionnaire-based study
por: Kamei, Daigo, et al.
Publicado: (2020)

Effect of tolvaptan on renal involvement in patients with autosomal dominant polycystic kidney disease according to different gene mutations
por: Moriyama, Tomofumi, et al.
Publicado: (2020)

Grading system utilising the total score of Oxford classification for predicting renal prognosis in IgA nephropathy
por: Miyabe, Yoei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pu50dob6q3ehhmn2dtf7rnsuj2